Renovaro Inc. (RENB) Total Debt to Capital

Renovaro Inc. (RENB) is creating a high-tech personalized therapy cycle where AI-driven big data analytics are combined with the production of cellular vaccines for early tumor detection, establishing significant barriers to entry for competitors. The price trend relative to the debt-to-equity ratio is 0.08. The business relies on outsourcing molecule synthesis and testing through CRO partners while maintaining full control over its intellectual property.

The stability of Renovaro Inc. (RENB) depends on its ability to fund costly developments in AI diagnostics and oncology without excessive debt load. By analyzing the total debt-to-equity ratio, an investor can see the proportion of borrowed funds relative to equity assets, which allows for an assessment of insolvency risk and the impact of leverage on the fair market value of the business.